# US 2026/0102242 A1 · Connective tissue to bone interface scaffolds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0102242 A1
- Document ID: US20260102242A1
- Status: Published application
- Kind: A1
- Application number: 19/328,099
- Filed: 2025-09-12
- Published: 2026-04-16
- Earliest claimed: 2019-10-18
- Assignees: Purdue Research Foundation; BioEnthesis Inc.; Advanced Regenerative Tech, Inc.
- Applicants: Purdue Research Foundation; BioEnthesis Inc.; Advanced Regenerative Tech, Inc.
- Inventors: Dushyanth R. SURAKANTI; Adam B. YANKE; Adam W. MARTINEZ; Kurt W.S. KLITZKE; Travis E. ENTROP; Dimitrios J. ANGELIS; Eric A. NAUMAN; Darryl A. DICKERSON
- Web page: https://patentgrep.com/patent/US20260102242A1

## CPC

- A61F 2/0811: {Fixation devices for tendons or ligaments}
- A61F 2/2846: {Support means for bone substitute or for bone graft implants, e.g. membranes or plates for covering bone defects (nets or sleeves applied to surface of endoprostheses A61F2/30907; bone plates A61B17/80; bone regeneration in dental surgery A61C8/0006)}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61F 2002/0823: {Modular anchors comprising a plurality of separate parts}
- A61F 2002/087: {Anchor integrated into tendons, e.g. bone blocks, integrated rings}
- A61F 2002/0876: {Position of anchor in respect to the bone}
- A61F 2002/2835: {Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material}
- A61F 2002/285: {Fixation appliances for attaching bone substitute support means to underlying bone}
- A61F 2002/30059: {differing in bone mineralization, e.g. made from both mineralized and demineralized adjacent parts}
- A61F 2002/30448: {using adhesives}
- A61F 2002/30461: {sutured, ligatured or stitched}
- A61F 2210/0076: multilayered, e.g. laminated structures
- A61F 2220/005: using adhesives
- A61F 2220/0075: sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
- A61F 2250/006: modular
- A61F 2310/00359: Bone or bony tissue
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Connective tissue-to-bone interface scaffolds (e.g., ligament-to-bone interface scaffolds, tendon-to-bone interface scaffolds, etc.). These scaffolds may be a single integrated implant or may be a modular (e.g., two-part) implant system.

## Claims

### Claim 1

A tissue-to-bone interface scaffold comprising a collagen-based porous network having a plurality of pores configured for guiding tissue differentiation and soft tissue regrowth, the tissue-to-bone scaffold including:
a first side of demineralized material including type I collagen configured for prevention of osteogenesis; and
a second side of mineralized material configured for osseointegration and fixation to bone;
wherein the first side is continuous with the second side; and
wherein the plurality of pores are present on the first and second side.

### Claim 2 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the collagen-based porous network is configured for binding biological factors to the plurality of pores.

### Claim 3 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, further comprising integrated materials including: hydrogels and extracellular matrix material.

### Claim 4 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the plurality of pores are trabeculae, wherein the trabeculae are configured for one or more of maintaining a pre-defined shaped of the scaffold, maintenance of nutrient transport, and differentiation of cell populations and vascularization.

### Claim 5 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the demineralized material includes bone decalcified via one or more of acid extraction, sonication in detergent solution alternated with rinsing in pure water, treatment with alkylammonium salts of EDTA, defatting by soaking acetone, treatment with hydrochloric acid, treatment with ethylene diamine tetraacetic acid (EDTA).

### Claim 6 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, further comprising peroxide treatment configured to remove osteoinductive factors.

### Claim 7 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, further comprising an ingrowth agent added to one or more of the demineralized or mineralized material and configured to enhance attachment of the scaffold to connective tissue and bone.

### Claim 8 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, further comprising one or more agent comprising: a pharmaceutical, an antibiotic, a growth factor, a hydrogel, a collagen gel and a stem cell, wherein the one or more agents are embedded, injected or attached to the scaffold.

### Claim 9 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, further comprising one or more of a polymeric carrier and matrix configured to contain and release one or more of a compound and cell type of interest including tendon progenitor cells; wherein the compound is combined with one or more of a carbohydrate, protein or polypeptide; wherein the compound is incorporated with the matrix; wherein the matrix is incorporated with the polymeric carrier.

### Claim 10 (depends on 9)

The tissue-to-bone interface scaffold of claim 9, wherein the matrix is comprised of one or more of: starch, cellulose, dextran, methylcellulose, hyaluronic acid, proteins, polypeptides, albumin, collagen and gelatin.

### Claim 11 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, further comprising a biocompatible layer, wherein the biocompatible layer is semipermeable.

### Claim 12 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the scaffold is comprised of one or more of: poly(E-caprolactone) (PCL), chitosan, heparin, chitosan-heparin complexes, biodegradable polymers and as poly (DL-lactide-coglycolide).

### Claim 13 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the scaffold is comprised of radio opaque materials including barium sulfate.

### Claim 14 (depends on 7)

The tissue-to-bone interface scaffold of claim 7, wherein the ingrowth agent includes one or more of: anti-inflammatory compounds, antibiotics, antiviral agents, oxidized regenerated cellulose and immunosuppressants.

### Claim 15 (depends on 14)

The tissue-to-bone interface scaffold of claim 14, wherein the ingrowth agent is configured to be incorporated with the scaffold during one or more of: before manufacture of the scaffold, after manufacture of the scaffold, before surgical placement of the scaffold, and after surgical placement of the scaffold.

### Claim 16 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the scaffold is configured for one or more of repair and replacement of joints, repair of ligaments, tendons, cartilage and growth plates.

### Claim 17 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the demineralized material originates as a mineralized material masked with one or more of a wax and polymer and configured to be demineralized.

### Claim 18 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the first and second sides are comprised of the same strip of cancellous bone.

### Claim 19 (depends on 1)

The tissue-to-bone interface scaffold of claim 1, wherein the first side and second side are configured to be separately formed and attached via an adhesive; wherein the adhesive is configured to maintain patency of the plurality of pores.

### Claim 20

A tissue-to-bone interface scaffold comprising a strip of cancellous bone including a collagen-based porous network having a plurality of pores configured for guiding tissue differentiation and soft tissue regrowth extending through the bone, the tissue-to-bone scaffold including:
a first side of demineralized material including type I collagen configured for prevention of osteogenesis; and
a second side of mineralized material configured for osseointegration and fixation to bone;
wherein the first side is continuous with the second side; and
wherein the plurality of pores are continuous between the first and second side.
